Search

everythinglearnresearchcommunity

for

Search:↓

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

GRF is not safe for tubal occlusion.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

A man developed skin lesions as a side effect of a gamma secretase inhibitor used for treating a tumor.

Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.

Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

GD-23 reduces anxiety by relying on neurosteroid production.

GLI2 increases follistatin production in human skin cells.

Finasteride significantly reduced tics and obsessive-compulsive symptoms in patients with Tourette syndrome.

Some drugs linked to growth hormones may increase the chance of hair loss in women.

TSG from Polygonum multiflorum may help with anti-aging by protecting the brain, heart, bones, and hair.

Tamsulosin's sulfonamide group may contribute to floppy iris syndrome.

The effect of GLP-1 RAs on erectile function is unclear and needs more research.

Anti-acne medications may work by reducing the activity of a protein involved in acne development.

Compound 6 is a promising candidate for better wound healing.

The compound GD-23 may reduce anxiety like diazepam by targeting the TSPO receptor.

Testosterone reduces knee movement, while flutamide and finasteride increase it.

Troglitazone increases subcutaneous fat in lipodystrophy patients.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.